Immune Response folds into Opticon Medical:
This article was originally published in Clinica
Immune Response, a publicly owned US company which was acquired by a privately owned development stage urology company in November last year, is to merge with the Delaware-domiciled Opticon. At the time of the merger it was announced that Immune shareholders would have just 20% of the new company. Opticon, based in Dublin, Ohio, is developing a silicone, disposable valved urinary tract catheter that does not require a system of collection tubes or bags. Immune Response has no connection with another company of the same name in California.